CD19 and acute lymphoblastic leukemia: Yan et al. 32 showed that patients with R/R B-ALL treated with CAR-T cells had a slightly higher efficacy than CD3 CD19 bispecific antibodies and was significantly higher than that in the traditional chemotherapy group.